Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer

Inclusion Criteria: * Diagnosis of prostate cancer confirmed by PSA and prostate biopsy * Male subjects, aged equal to or over 50 years * Organ-confined prostate cancer, clinical stage T1a, b, or c or T2a * At least one positive biopsy within the previous 6 months * PSA equal to or less than 10 ng/ml * Gleason score equal to or less than 6 * Histological grading of 3+3, 3+2, 2+3, 2+4, or 2+2 based upon the baseline transrectal ultrasound (TRUS)-guided 10 core biopsy results. A subject with a histological grading of primary 4 will not be permitted for study enrollment. * Prostate volume equal to or less than 40 cc * Prostate anteroposterior (AP) diameter equal to or less than 25 mm * Normal rectal anatomy and rectal mucosa * Maximum rectal wall measurement 6 mm * The Investigator has completed a medical history and a physical examination to assure that the subjects meet all study enrollment criteria * The subject is willing and able to read, understand, and sign the study specific informed consent form * The subject agrees to comply with study protocol requirements, including HIFU or cryotherapy treatment and all follow up visit requirements through 24 months of follow up treatment. Exclusion Criteria: * Evidence of seminal vesicle involvement * Evidence of lymph node involvement or metastasis * Any previous treatment for prostate cancer including: external beam radiation therapy (EBRT), hormone therapy and/or previous bilateral orchiectomy * Previous surgery or procedure of the prostate (except prostate biopsy) or urethra within the prior one year * Calcification inducing a shadow in the prostate which cannot be included in the targeted volume * Large median lobe of the prostate which cannot be included in the target volume * Use within the previous 2 months of finasteride * Previous rectal surgery (other than hemorrhoidectomy) or history of rectal disease * Active inflammatory bowel syndrome * Current superficial bladder cancer, urethral stricture, or bladder neck contracture * Active urinary tract infection or prostatitis (the subject may be enrolled once the infection has been treated and has resolved) * Compromised renal function or upper urinary tract disease as a result of urinary obstruction * A history of bleeding disorders/coagulopathy or ongoing treatment for this condition * Urinary tract or rectal fistula * Rectal fibrosis, rectal stenosis, or other anomalies making the Ablatherm Integrated Imaging rectal probe insertion difficult * Anatomical anomaly of the rectum or anomaly of the rectal mucous membrane * Prostate seroma, prostate abscess, or urethral stenosis * An intraprostatic implant such as a stent or catheter, or any implant or prosthesis at less than 1 cm from the prostate * Interest in future fertility * Concurrent illness, disability, or geographical residence would hamper attendance at required study visits * Known latex hypersensitivity * Current participation in another clinical investigation of a medical device or a drug or has participated in such a study within 30 days prior to study enrollment * The Investigator believes that the subject will be unwilling or unable to comply with study protocol requirements, including the HIFU or cryotherapy procedure and study-related follow up visit requirements.